|
시장보고서
상품코드
1360024
폰빌레브란트병(vWD) 시장 : 기회 평가, 역학, 질환 관리, 임상시험, 미충족 요구, 예측(-2032년)von Willebrand Disease (vWD) Market Opportunity Assessment, Epidemiology, Disease Management, Clinical Trials, Unmet Needs and Forecast to 2032 |
||||||
폰빌레브란트병(vWD)의 유병률은 주요 3개국의 인구증가에 수반하여 AGR 0.61%로 꾸준히 증가하고 있습니다. 현재 3MM에서 vWD의 치료 레지멘은 대부분이 DDAVP와 응고 제VIII 인자＋vWF 복합체에 한정되어 있습니다. 이 영역에는 vWD의 진단 툴 개선 및 중증 vWD에 대한 치료법 개선 등 몇개의 미충족 요구가 있습니다.
vWD 후기 연구개발 파이프라인은 소아용 vWF 재조합, RNA 올리고뉴클레오티드 요법 BT-200의 개발에 중점을 두고 있습니다. vWD 인구의 꾸준한 증가와 신규 치료제의 시장 참여에 의해 예측 기간 중 큰 성장이 전망됩니다.
폰빌레브란트병(vWD) 시장에 대해 조사했으며, 주요 3개국(미국, 독일, 영국)의 동향과 연간 치료비, 2032년까지 10년간의 예측과 함께 시장 특성과 미충족 요구, 파이프라인 동향 등을 제공하고 있습니다.
목차
제1장 주요 요약
제2장 질병의 개요
- 폰빌레브란트병의 개요
- 폰빌레브란트병의 분류
제3장 역학
- 쿠싱증후군으로 진단된 이환 증례, 2020-2030년
- 정보원과 조사 방법
제4장 현재의 치료 옵션
- 치료 패러다임
- 시판 제품
- 제품 개요 : 혈장 유래 FVIII, 혈장 유래 vWF, 응고 제VIII 인자(인간)+ 폰빌레브란트인자 복합체(인간), 아세트산 데스모프레신, Vonvendi(미국)/Veyvondi(EU)(성인용)
제5장 미충족 요구와 기회
- 폰빌레브란트병에서의 미충족 요구
- 중증 vWD에 대한 개선된 치료법
- 더 나은 진단 툴
- 환자와 의사 교육의 강화
- 건강 격차에 대한 대처
- 비용 효과가 높은 치료법
제6장 파이프라인 평가
- 폰빌레브란트병 파이프라인의 개요
- 주요 파이프라인 에이전트
- 제품 개요 : Vonvendi(미국)/Veybondi(EU)(소아용), Takeda
- 제품 개요 : BT-200-Guardian Therapeutics
- 심사 지정
- 폰빌레브란트병 : 임상시험(제II/III상)의 개요
제7장 연구개발 전략
- 폰빌레브란트병에서 임상시험 디자인의 동향
- 폰빌레브란트병에서 거래의 동향
제8장 시장의 전망
- 폰빌레브란트병 판매 예측
- 폰빌레브란트병 시장 예측
- 시장 촉진요인과 장벽
제9장 부록
제10장 문의
KSA 23.10.25Abstract
The prevalence of vWD is increasing at a steady rate, in line with population growth in the 3MM, at an AGR of 0.61%.
Currently, the treatment regimen for vWD in the 3MM is mostly limited to DDAVP and coagulation factor VIII + vWF complex.
There are several unmet needs in this space, including the need for better diagnostic tools for vWD and improved therapies for severe vWD.
The vWD late-stage R&D pipeline is focused on developing vWF recombinant for pediatric use, RNA oligonucleotide therapy BT-200.
Significant growth is expected throughout the forecast period as the vWD population steadily increases and novel therapies enter the market.
Key Highlights
Report deliverables include a Pdf report and Excel-based forecast model
Forecast includes three countries: US, Germany, and the UK
Forecasts cover three time points: base year, 5-year, and 10-year
Scope
- Overview of vWD, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized vWD therapeutics market revenue in 3MM (US, Germany and the UK), annual cost of therapy and treatment usage pattern in 2022 and forecast for 10 years to 2032; forecast covers three time points: base year, 5-year, and 10-year.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the vWD therapeutics market.
- Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for vWD treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the 3MM vWD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the vWD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the vWD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Table of Contents
1 Executive Summary
- 1.1 Executive Summary
2 Disease Overview
- 2.1 Overview of von Willebrand Disease
- 2.2 Classification of von Willebrand Disease
3 Epidemiology
- 3.1 Diagnosed Prevalent Cases of Cushing's Syndrome, 2020-2030
- 3.2 Sources and Methodology
4 Current Treatment Options
- 4.1 Treatment Paradigm
- 4.2 Marketed Products
- 4.3 Product Profiles: Plasma-Derived FVIII, Plasma Derived vWF, Coagulation Factor VIII (Human) + von Willebrand Factor Complex (Human), Desmopressin Acetate, Vonvendi (US)/Veyvondi (EU) (For Adult Use)
5 Unmet Needs and Opportunities
- 5.1 Unmet Needs in von Willebrand Disease
- 5.2 Improved Therapies for Severe vWD
- 5.3 Better Diagnostic Tools
- 5.4 Increased Patient and Physician Education
- 5.5 Addressing Health Disparities
- 5.6 Cost-Effective Therapies
6 Pipeline Assessment
- 6.1 von Willebrand Disease Pipeline Overview
- 6.2 Leading Pipeline Agents
- 6.3 Product Profile:. Vonvendi (US)/Veybondi (EU) (For Pediatric Use), Takeda
- 6.4 Product Profile: BT-200 - Guardian Therapeutics
- 6.5 Review Designations
- 6.6 von Willebrand Disease: Clinical Trials (Phase II/III) Overview
7 R&D Strategies
- 7.1 Trends in Clinical Trial Design in von Willebrand Disease
- 7.2 Trends in Deal-Making in von Willebrand Disease
8 Market Outlook
- 8.1 von Willebrand Disease Sales Forecast
- 8.2 von Willebrand Disease Market Forecast
- 8.3 Market Drivers and Barriers
9 Appendix
- 9.1 Primary Research: KOL Information
- 9.2 About the Authors
